NGN Capital et al. in $40.3m Endosense series-C round

Existing investors that participated in the deal included Edmond de Rothschild Investment Partners (EdRIP), Gimv, NeoMed Management, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and Endosense employees.

The new capital will be used to commercialise Endosense's latest product, TactiCath Quartz, across Europe, and fund the FDA submission of the product in the US.

In September 2009, Endosense received CHF 38m from lead investor EdRIP and Gimv, NeoMed, VI, Sectoral, Ysios and Initiative Capital Romandie. The company's first funding round was closed on CHF 22.6m in 2005.

Company
Endosese is a Geneva-based medical technology company that focuses on catheter ablation for the treatment of cardiac arrhytmias. The company was founded in 2003.

People
Following the transaction, NGN managing general partner Peter Johann will join Endosense's board of directors. Jan Keltjens is president and CEO of the company. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Now researching
• Healthcare
• Switzerland
• Gimv